Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.80 Insider Own27.57% Shs Outstand121.67M Perf Week7.73%
Market Cap168.96M Forward P/E- EPS next Y-0.43 Insider Trans-1.44% Shs Float121.16M Perf Month29.26%
Income-111.14M PEG- EPS next Q-0.15 Inst Own36.11% Short Float10.92% Perf Quarter35.63%
Sales0.00M P/S- EPS this Y59.87% Inst Trans67.66% Short Ratio6.45 Perf Half Y-24.06%
Book/sh0.41 P/B2.46 EPS next Y29.27% ROA-77.53% Short Interest13.23M Perf Year6.32%
Cash/sh0.85 P/C1.19 EPS next 5Y- ROE-171.72% 52W Range0.57 - 2.58 Perf YTD20.45%
Dividend Est.- P/FCF- EPS past 5Y69.68% ROI-89.08% 52W High-60.78% Beta0.44
Dividend TTM- Quick Ratio5.81 Sales past 5Y-25.00% Gross Margin- 52W Low76.48% ATR (14)0.07
Dividend Ex-Date- Current Ratio5.81 EPS Y/Y TTM71.77% Oper. Margin0.00% RSI (14)60.67 Volatility9.01% 8.43%
Employees70 Debt/Eq0.86 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price3.26
Option/ShortYes / Yes LT Debt/Eq0.85 EPS Q/Q95.55% Payout- Rel Volume1.24 Prev Close0.97
Sales Surprise- EPS Surprise93.28% Sales Q/Q- EarningsNov 09 BMO Avg Volume2.05M Price1.01
SMA2010.38% SMA5019.88% SMA200-17.81% Trades Volume2,543,038 Change4.06%
Date Action Analyst Rating Change Price Target Change
Dec-12-23Downgrade B. Riley Securities Buy → Neutral $3 → $1
Aug-30-23Resumed B. Riley Securities Buy $3
Dec-22-22Initiated Cantor Fitzgerald Overweight $3
Dec-12-22Initiated Piper Sandler Overweight $3
Dec-23-19Initiated Oppenheimer Outperform $20
Dec-18-19Initiated ROTH Capital Buy $20
Dec-09-19Upgrade Citigroup Neutral → Buy $16 → $20
Dec-05-19Initiated B. Riley FBR Buy
Jun-07-19Initiated Stifel Buy $27
Jun-05-19Initiated Cowen Outperform
Mar-01-24 04:05PM
Feb-01-24 04:05PM
Dec-09-23 12:00PM
Dec-04-23 04:05PM
Nov-10-23 03:46PM
08:00AM Loading…
Nov-09-23 09:29AM
Nov-02-23 08:00AM
Nov-01-23 04:05PM
Oct-31-23 08:00AM
Oct-18-23 08:00AM
Oct-02-23 04:05PM
Sep-19-23 08:00AM
08:00AM Loading…
Sep-06-23 08:00AM
Sep-05-23 08:00AM
Sep-01-23 04:05PM
Aug-15-23 10:53AM
Aug-10-23 06:38AM
Aug-08-23 04:05PM
Aug-03-23 08:00AM
Aug-02-23 08:01AM
Jun-30-23 04:05PM
Jun-14-23 06:26AM
Jun-13-23 08:00AM
Jun-02-23 04:05PM
May-16-23 04:01PM
04:44AM Loading…
May-15-23 04:44AM
May-04-23 06:12AM
Apr-26-23 12:32PM
Apr-12-23 08:00AM
Apr-04-23 04:05PM
Mar-24-23 07:36AM
Mar-21-23 06:05AM
Mar-07-23 08:01AM
Mar-02-23 04:05PM
Jan-31-23 12:00PM
Dec-12-22 08:30AM
Dec-07-22 08:43AM
Dec-06-22 06:26PM
Nov-30-22 08:05AM
Nov-29-22 04:01PM
Nov-17-22 09:51AM
Nov-08-22 08:00AM
Nov-04-22 04:05PM
Nov-03-22 06:05AM
Oct-26-22 08:00AM
Oct-20-22 08:00AM
Sep-27-22 10:49AM
Aug-31-22 08:30AM
Aug-18-22 12:00PM
Aug-08-22 04:05PM
Aug-04-22 07:05AM
Jul-26-22 04:05PM
Jul-21-22 02:46PM
Jul-20-22 04:10PM
Jul-01-22 04:30PM
Jun-30-22 07:52PM
Jun-23-22 07:00AM
May-16-22 06:05AM
May-12-22 07:15AM
May-03-22 06:05AM
May-02-22 04:05PM
Apr-08-22 01:05PM
Apr-04-22 08:05AM
Apr-01-22 04:05PM
Mar-17-22 06:05AM
Mar-08-22 08:00AM
Mar-03-22 08:00AM
Mar-01-22 10:15AM
Feb-02-22 04:05PM
Jan-19-22 08:00AM
Jan-05-22 04:05PM
Dec-13-21 12:52PM
Dec-11-21 09:00AM
Dec-02-21 06:05AM
Dec-01-21 04:05PM
Nov-10-21 08:00AM
Nov-04-21 09:01AM
Nov-01-21 04:05PM
Oct-25-21 08:00AM
Oct-19-21 08:00AM
Oct-04-21 08:00AM
Oct-01-21 04:05PM
Sep-28-21 10:11AM
Sep-15-21 04:05PM
Sep-08-21 08:00AM
Sep-01-21 04:01PM
Aug-04-21 04:01PM
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mostafa Adam S.Chief Financial OfficerFeb 12Sale1.0127,72127,97352,500Feb 12 05:03 PM
Ragan PaulaPresident and CEOFeb 12Sale1.0121,69521,892814,746Feb 12 05:05 PM
DiBiase MaryChief Operating OfficerFeb 12Sale1.013,6833,709307,161Feb 12 05:23 PM
Taveras ArthurChief Scientific OfficerFeb 12Sale1.01787793248,536Feb 12 05:23 PM
Ragan PaulaPresident and CEONov 03Sale0.9039,90635,915836,441Nov 03 05:26 PM
Mostafa Adam S.Chief Financial OfficerNov 01Sale0.73230,645168,37180,221Nov 03 04:42 PM
Ragan PaulaPresident and CEONov 01Sale0.73199,531145,658876,347Nov 03 05:26 PM
DiBiase MaryChief Operating OfficerNov 01Sale0.7367,69549,417310,844Nov 03 04:40 PM
Taveras ArthurChief Scientific OfficerNov 01Sale0.7367,69549,417249,323Nov 03 04:39 PM
Baldry MarkChief Commercial OfficerNov 01Sale0.7310,2577,48824,690Nov 03 04:39 PM
DiBiase MaryChief Operating OfficerSep 08Sale1.252,6423,300147,894Sep 12 04:04 PM
WYZGA MICHAEL SDirectorAug 18Buy1.2025,00029,87576,667Aug 22 04:09 PM
Stewart MurrayInterim Chief Medical OfficerAug 10Sale1.06130,056137,859146,504Aug 11 07:26 PM
Mostafa Adam S.Chief Financial OfficerJun 30Sale1.892,6414,99180,221Jul 05 04:04 PM
DiBiase MaryChief Operating OfficerJun 30Sale1.89464877150,536Jul 05 04:05 PM
Ragan PaulaPresident and CEOJun 23Sale1.926,72412,910543,797Jun 26 04:11 PM
Mostafa Adam S.Chief Financial OfficerJun 23Sale1.935,41710,45582,862Jun 26 04:13 PM
DiBiase MaryChief Operating OfficerJun 23Sale1.938571,654151,000Jun 26 04:15 PM
Ragan PaulaPresident and CEOJun 15Sale2.236,72414,995550,521Jun 16 04:15 PM
Mostafa Adam S.Chief Financial OfficerJun 15Sale2.225,41712,02688,279Jun 16 04:17 PM
DiBiase MaryChief Operating OfficerJun 15Sale2.238571,911151,857Jun 16 04:24 PM
Ragan PaulaPresident and CEOMay 31Sale1.956,29212,269557,245May 31 05:05 PM
Mostafa Adam S.Chief Financial OfficerMar 10Sale0.8452,50044,10093,696Mar 13 04:50 PM
Ragan PaulaPresident and CEOMar 10Sale0.8449,67841,730563,537Mar 13 04:46 PM
DiBiase MaryChief Operating OfficerMar 10Sale0.8418,19215,281152,714Mar 13 04:52 PM
Taveras ArthurChief Scientific OfficerMar 10Sale0.8416,80614,11786,373Mar 13 04:48 PM